Professional Documents
Culture Documents
2018 Atezo Carbo Etop SCLC
2018 Atezo Carbo Etop SCLC
Original Article
A BS T R AC T
BACKGROUND
The authors’ full names, academic de‑ Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1
grees, and affiliations are listed in the (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treat-
Appendix. Address reprint requests to Dr.
Horn at Vanderbilt University Medical Cen‑ ment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition
ter, 2220 Pierce Ave., 777 PRB, Nashville, with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.
TN 37232, or at leora.horn@vumc.org.
RESULTS
A total of 201 patients were randomly assigned to the atezolizumab group, and 202
patients to the placebo group. At a median follow-up of 13.9 months, the median
overall survival was 12.3 months in the atezolizumab group and 10.3 months in
the placebo group (hazard ratio for death, 0.70; 95% confidence interval [CI], 0.54
to 0.91; P = 0.007). The median progression-free survival was 5.2 months and 4.3
months, respectively (hazard ratio for disease progression or death, 0.77; 95% CI,
0.62 to 0.96; P = 0.02). The safety profile of atezolizumab plus carboplatin and
etoposide was consistent with the previously reported safety profile of the indi-
vidual agents, with no new findings observed.
CONCLUSIONS
The addition of atezolizumab to chemotherapy in the first-line treatment of exten-
sive-stage small-cell lung cancer resulted in significantly longer overall survival
and progression-free survival than chemotherapy alone. (Funded by F. Hoffmann–
La Roche/Genentech; IMpower133 ClinicalTrials.gov number, NCT02763579.)
S
tandard-of-care first-line treat- written informed consent. An independent data
ment for extensive-stage small-cell lung and safety monitoring committee reviewed safety
A Quick Take
cancer is platinum chemotherapy (carbo- data regularly. Protocol approval was obtained is available at
platin or cisplatin) with etoposide.1-3 Despite re- from an independent ethics committee at each NEJM.org
sponse rates of 60 to 65%, limited progress has site. The protocol is available with the full text
been made in more than two decades; outcomes of this article at NEJM.org. An author who is an
remain poor, with a median overall survival of employee of F. Hoffmann–La Roche and an au-
approximately 10 months.3,4 Small-cell lung can- thor who is an employee of Genentech analyzed
cer has a high mutation rate, which suggests that the data. All the authors vouch for the accuracy
these tumors may be immunogenic and could and completeness of the data and for the fidelity
respond to immune-checkpoint inhibitors.5-7 of the trial to the protocol. All drafts of the
Adding immunotherapy to chemotherapy may manuscript were prepared by the authors, with
enhance antitumor immunity and improve out- editorial and writing assistance funded by the
comes beyond those achieved with our current sponsor.
therapeutic armamentarium. Clinical activity of
immunotherapies has been observed in patients Patients
with refractory or metastatic small-cell lung Eligible patients were adults with histologically or
cancer 8-12; however, a phase 2 single-group study cytologically confirmed extensive-stage small-cell
of maintenance pembrolizumab and a phase 3 lung cancer as defined according to the Veterans
study of ipilimumab plus chemotherapy showed Administration Lung Study Group staging sys-
no improved efficacy in the first-line treatment tem (Table S1 in the Supplementary Appendix,
of extensive-stage small-cell lung cancer.12,13 available at NEJM.org),16 measurable extensive-
Atezolizumab (Tecentriq, F. Hoffmann–La stage small-cell lung cancer according to Response
Roche/Genentech) is a humanized monoclonal Evaluation Criteria in Solid Tumors (RECIST),
anti–programmed death ligand 1 (PD-L1) anti- version 1.1, and an Eastern Cooperative Oncol-
body that inhibits PD-L1–programmed death 1 ogy Group (ECOG) performance-status score of
(PD-1) and PD-L1–B7-1 signaling and restores 0 or 1 (on a 5-point scale, with higher numbers
tumor-specific T-cell immunity.14,15 In a phase 1 reflecting greater disability) who had not received
trial, atezolizumab monotherapy had an accept- previous systemic treatment for extensive-stage
able side-effect and safety profile, with promising small-cell lung cancer. Patients with treated asymp-
durability of response in patients with relapsed tomatic central nervous system metastases were
or refractory small-cell lung cancer.10 eligible (see the Supplementary Methods section
The IMpower133 trial evaluated the efficacy in the Supplementary Appendix). Key exclusion
and safety of adding atezolizumab or placebo to criteria were a history of autoimmune disease
first-line treatment with carboplatin and etopo- and previous treatment with CD137 agonists or
side in patients with extensive-stage small-cell immune-checkpoint blockade therapies.
lung cancer. We report a planned interim analy-
sis of overall survival and a final analysis of Trial Design and Interventions
progression-free survival. The IMpower133 trial is a multinational, phase 1
(safety) and phase 3 (efficacy), double-blind, ran-
domized, placebo-controlled trial. Enrolled pa-
Me thods
tients were assigned in a 1:1 ratio to receive, in
Trial Oversight the induction phase, four 21-day cycles of carbo-
F. Hoffmann–La Roche/Genentech sponsored the platin (area under the curve of 5 mg per milli-
IMpower133 trial, provided the trial drugs, and liter per minute, administered intravenously on
collaborated with the academic authors on the day 1 of each cycle) and etoposide (100 mg per
design of the trial and on the collection, analy- square meter of body-surface area, administered
sis, and interpretation of the data. The trial was intravenously on days 1 through 3 of each cycle)
conducted in accordance with Good Clinical with either atezolizumab (at a dose of 1200 mg,
Practice guidelines and the provisions of the administered intravenously on day 1 of each cycle)
Declaration of Helsinki. All patients provided or placebo (Fig. S1 in the Supplementary Appen-
dix). The induction phase was followed by a main- rates were reported in the interest of rigor and
tenance phase during which patients received to protect against potential bias. The estimated
either atezolizumab or placebo (according to the rate of overall survival at 1 year was evaluated.
previous random assignment) until the occur- Exploratory analyses included the assessment of
rence of unacceptable toxic effects or disease efficacy according to tumor mutational burden.
progression according to RECIST. Continuation Assessments of tumor mutational burden were
of the trial regimen after the occurrence of dis- performed with the use of a blood-based assay
ease progression during either phase was allowed (blood-based tumor mutational burden), as re-
if evidence of clinical benefit existed (see the ported previously.19
Supplementary Methods section in the Supple- Tumor assessments were conducted at screen-
mentary Appendix). During the maintenance ing, every 6 weeks for the first 48 weeks starting
phase, prophylactic cranial irradiation was per- from day 1 of cycle 1, and every 9 weeks there-
mitted, but thoracic radiation therapy was not. after until the occurrence of disease progression
Randomization was performed with the use of a according to RECIST. Patients who continued
permuted-block randomization method (IxRS) the trial regimen beyond disease progression
and was stratified according to sex, ECOG per- continued to undergo tumor assessments every
formance-status score (0 or 1), and presence of 6 weeks until the regimen was discontinued. Ad-
brain metastases (yes or no). PD-L1 testing was verse events were assessed according to National
not performed during screening owing to the Cancer Institute Common Terminology Criteria
expected high rate of inadequate sample types for Adverse Events, version 4.0. The investigators
(e.g., fine-needle aspirates, bronchoscopy find- determined whether adverse events were related
ings), the low prevalence of PD-L1 expression on to the trial regimen.
tumor cells, and the lack of an association be-
tween response and PD-L1 expression in the Statistical Analysis
phase 1 trial of atezolizumab in extensive-stage The primary end points were assessed in the
small-cell lung cancer.8-10,17,18 intention-to-treat population and were analyzed
Phase 1 of the trial was a safety run-in period according to the assigned treatment, regardless
to establish the side-effect and adverse-event pro- of the actual treatment received. For the analysis
file of the treatment regimens; during this phase, of progression-free survival, data for patients who
a minimum of 12 patients were assigned to each were alive and had no disease progression were
group and received at least two cycles of treat- censored at the time of the last tumor assess-
ment. Trial treatments were administered at full ment. For the analysis of overall survival, data
dose according to the protocol. Unblinded safety for patients who were alive were censored at the
data were reviewed by an independent data and time of the last contact.
safety monitoring committee for assessment of To control the overall two-sided type I error
the side-effect profile; on the basis of the find- rate of 0.05, a group-sequential weighted Holm
ings of the committee, the trial continued as a procedure20,21 was used wherein the two-sided
randomized phase 3 trial. significance levels of 0.005 and 0.045 were allo-
cated to the primary comparisons for progression-
End Points and Assessments free survival and overall survival, respectively. The
The primary end points were overall survival (the test that was significant could pass its alpha
time from randomization to death from any level to the test that was not statistically signifi-
cause) and investigator-assessed progression-free cant at the original allocated alpha level.
survival (the time from randomization to disease The sample size of the trial was determined
progression according to RECIST or death from by the analysis of overall survival. We calculated
any cause, whichever occurred first) in the inten- that 306 deaths in the intention-to-treat popula-
tion-to-treat population. Key secondary end points tion would be needed to provide 91% power at a
included investigator-assessed objective response two-sided significance level of 0.045 to detect
rate (according to RECIST) and the duration of a hazard ratio for death with atezolizumab as
response. Confirmation of responses was not compared with placebo of 0.68, with the use of
required per protocol, but confirmed response a log-rank test. One interim analysis of overall
R e sult s
In the intention-to-treat population, 104 pa-
Patients tients in the atezolizumab group and 116 in the
Between June 6, 2016, and May 31, 2017, a total placebo group received at least one subsequent
of 403 patients were enrolled at 106 sites in 21 therapy (Table S4 in the Supplementary Appen-
countries and were randomly assigned to the dix). Fifteen patients in the placebo group re-
atezolizumab group (201 patients) or the placebo ceived subsequent immunotherapy.
group (202 patients) (Fig. 1). Baseline character-
istics were well balanced between the groups Overall Survival Analysis
(Table 1, and Tables S2 and S3 in the Supple- At the time of data cutoff, the median follow-up
mentary Appendix). Twenty-two patients in each was 13.9 months. A total of 104 patients (51.7%)
group received prophylactic cranial irradiation. in the atezolizumab group and 134 patients
(66.3%) in the placebo group had died. Overall Progression-free Survival Analysis
survival was significantly longer in the atezolizu A total of 171 patients (85.1%) in the atezolizu
mab group (median, 12.3 months; 95% confi- mab group and 189 patients (93.6%) in the pla-
dence interval [CI], 10.8 to 15.9) than in the cebo group had disease progression or died.
placebo group (median, 10.3 months; 95% CI, Progression-free survival was longer in the atezo
9.3 to 11.3). The stratified hazard ratio for death lizumab group (median, 5.2 months; 95% CI,
was 0.70 (95% CI, 0.54 to 0.91; P = 0.007) (Fig. 2A), 4.4 to 5.6) than in the placebo group (median,
and the 1-year overall survival rate was 51.7% in 4.3 months; 95% CI, 4.2 to 4.5). The stratified
the atezolizumab group and 38.2% in the pla- hazard ratio for disease progression or death
cebo group. was 0.77 (95% CI, 0.62 to 0.96; P = 0.02) (Fig. 2B).
A Overall Survival
100 Rate of Overall Survival at 12 Mo
90 Atezolizumab 51.7% (95% CI, 44.4–59.0)
Placebo 38.2% (95% CI, 31.2–45.3)
80
B Progression-free Survival
100 Rate of Progression-free Survival
90 at 6 mo at 12 mo
Patients Who Survived without
Exploratory subgroup analyses showed no in the two groups, and the incidence and types of
clear suggestion that blood-based tumor muta- immune-related adverse events were similar to
tional burden levels at either cutoff (10 or 16 those seen with atezolizumab monotherapy.26-28
mutations per megabase) were predictive of ben- One randomized, phase 3 study assessed an
efit with atezolizumab in this population. These immunotherapy (ipilimumab) plus chemotherapy
results are in contrast to previous studies that as compared with chemotherapy alone in the
suggested an association between high tumor first-line treatment of patients with extensive-
mutational burden and better clinical outcomes stage small-cell lung cancer, but no significant
in patients receiving cancer immunotherapies.24,25 difference in overall survival between the two
A possible explanation for the lack of greater groups was noted.13 Ipilimumab targets CTLA-4
benefit with respect to clinical outcomes in pa- and stimulates peripheral T-cell activation but
tients with high blood-based tumor mutational does not activate T cells in the tumor microen-
burden in this trial is that the combination of vironment; given this mechanism of action,
platinum and etoposide is highly active and also Reck and colleagues speculated that ipilimumab
highly myelosuppressive. may be of limited value when added to chemo-
In this trial, exposure to chemotherapy was therapy in patients with this disease.13 One pos-
maintained with the addition of atezolizumab. sible explanation for the effectiveness of atezo
Rates of hematologic side effects were similar lizumab in addition to chemotherapy in the
IMpower133 trial may be that carboplatin and
Figure 2 (facing page). Overall Survival and Investigator- etoposide might not deplete the intratumoral
Assessed Progression-free Survival in the Intention-to- T-cell population, and atezolizumab may be able
Treat Population. to activate the intratumoral T lymphocytes to
Panel A shows the Kaplan–Meier estimates of overall exert an antitumor effect; however, further stud-
survival, and Panel B the Kaplan–Meier estimates of ies are needed to confirm this hypothesis.
investigator-assessed progression-free survival. Tick
marks indicate censored data. Panel C shows a sub‑
In addition, a single-group, phase 2 study
group analysis of overall survival according to baseline of maintenance pembrolizumab in extensive-
characteristics. Eastern Cooperative Oncology Group stage small-cell lung cancer did not show lon-
(ECOG) performance-status scores range from 0 to 5, ger progression-free survival or overall survival
with higher scores reflecting greater disability. Tumor when compared with historical data.12 In con-
mutational burden was assessed with the use of a
blood-based assay.
trast, the current trial showed a significant im-
provement in progression-free survival and over-
* The date of data cutoff was April 24, 2018. Multiple occurrences of the same adverse event in one patient were counted once at the highest
grade for the preferred term. The incidence of treatment-related adverse events associated with any component of the trial regimen is shown.
all survival with the addition of atezolizumab this disease showed that the addition of atezoliz
to chemotherapy as first-line treatment. This umab to carboplatin and etoposide was associ-
suggests that combining checkpoint inhibition ated with significantly longer overall survival and
with cytotoxic therapy during induction may be progression-free survival, with a safety profile
beneficial and potentially necessary to improve consistent with the defined toxic effects of the
overall survival beyond that seen with the cur- individual agents.
rent standard of care, and thus it may be a pre- A data sharing statement provided by the authors is available
ferred treatment approach over maintenance with the full text of this article at NEJM.org.
checkpoint-inhibitor therapy alone. Further studies Supported by F. Hoffmann–La Roche/Genentech, a member of
the Roche Group.
directly comparing the two treatment approaches Disclosure forms provided by the authors are available with the
are needed. full text of this article at NEJM.org.
In summary, this multinational trial in the We thank Daniel Waterkamp of Genentech for his contribu-
tion to the trial design; and Rachel Johnson, Ph.D., and Daniel
first-line treatment of extensive-stage small-cell Clyde, Ph.D., of Health Interactions for third-party writing assis-
lung cancer in a patient population typical for tance (funded by Genentech).
Appendix
The authors’ full names and academic degrees are as follows: Leora Horn, M.D., Aaron S. Mansfield, M.D., Aleksandra Szczęsna, M.D.,
Libor Havel, M.D., Maciej Krzakowski, M.D., Ph.D., Maximilian J. Hochmair, M.D., Florian Huemer, M.D., György Losonczy, M.D.,
Ph.D., Melissa L. Johnson, M.D., Makoto Nishio, M.D., Ph.D., Martin Reck, M.D., Tony Mok, M.D., Sivuonthanh Lam, Pharm.D.,
David S. Shames, Ph.D., Juan Liu, Ph.D., Beiying Ding, Ph.D., Ariel Lopez‑Chavez, M.D., Fairooz Kabbinavar, M.D., Wei Lin, M.D., Alan
Sandler, M.D., and Stephen V. Liu, M.D.
The authors’ affiliations are as follows: Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute–Tennes-
see Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock
(A. Szczęsna), and Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) — both in Poland; Thom-
ayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical
Care Medicine (M.J.H.) and the 2nd Department of Respiratory and Critical Care Medicine (F.H.), Ludwig Boltzmann Institute for COPD
and Respiratory Epidemiology–Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Vienna; Semmelweis Egyetem
ÁOK, Pulmonológiai Klinika, Budapest, Hungary (G.L.); the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
(M.N.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany
(M.R.); State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.), and F. Hoffmann–La Roche, Shang-
hai (J.L.) — both in China; Genentech, South San Francisco, CA (S.L., D.S.S., B.D., A.L.-C., F.K., W.L., A. Sandler); and Georgetown
University, Washington DC (S.V.L.).
References
1. NCCN clinical practice guidelines in Clinical activity, safety and predictive bio- et al. Blood-based tumor mutational bur-
oncology:small cell lung cancer, version markers results from a phase Ia atezoliz den as a predictor of clinical benefit in
2.2018 (https://www.nccn.org/about/news/ umab (atezo) trial in extensive-stage small non-small-cell lung cancer patients treated
ebulletin/ebulletindetail.aspx?ebulletinid= cell lung cancer (ES-SCLC). Ann Oncol with atezolizumab. Nat Med 2018; 24:
1318). 2016;27:Suppl 6:1425PD. abstract. 1441-8.
2. Stahel R, Thatcher N, Früh M, et al. 11. Diaz LA, Marabelle A, Delord J, Shapira- 20. Ye Y, Li A, Liu L, Yao B. A group se-
1st ESMO Consensus Conference in lung Frommer R, Geva R, Peled N. Pembroliz quential Holm procedure with multiple
cancer; Lugano 2010: small-cell lung can- umab therapy for microsatellite instability primary endpoints. Stat Med 2013; 32:
cer. Ann Oncol 2011;22:1973-80. high (MSI-H) colorectal cancer (CRC) and 1112-24.
3. Farago AF, Keane FK. Current stan- non-CRC. J Clin Oncol 2017;35:Suppl:3071. 21. Dmitrienko A, D’Agostino RB Sr. Mul-
dards for clinical management of small abstract. tiplicity considerations in clinical trials.
cell lung cancer. Transl Lung Cancer Res 12. Gadgeel SM, Pennell NA, Fidler MJ, N Engl J Med 2018;378:2115-22.
2018;7:69-79. et al. Phase II study of maintenance pem- 22. DeMets DL, Lan KK. Interim analysis:
4. Socinski MA, Smit EF, Lorigan P, et al. brolizumab in patients with extensive- the alpha spending function approach.
Phase III study of pemetrexed plus carbo- stage small cell lung cancer (SCLC). J Thorac Stat Med 1994;13:1341-52.
platin compared with etoposide plus car- Oncol 2018;13:1393-9. 23. Brookmeyer R, Crowley J. A confi-
boplatin in chemotherapy-naive patients 13. Reck M, Luft A, Szczesna A, et al. dence interval for the median survival
with extensive-stage small-cell lung can- Phase III randomized trial of ipilimumab time. Biometrics 1982;38:29-41.
cer. J Clin Oncol 2009;27:4787-92. plus etoposide and platinum versus place- 24. Hellmann MD, Callahan MK, Awad
5. Rudin CM, Durinck S, Stawiski EW, bo plus etoposide and platinum in exten- MM, et al. Tumor mutational burden and
et al. Comprehensive genomic analysis sive-stage small-cell lung cancer. J Clin efficacy of nivolumab monotherapy and
identifies SOX2 as a frequently amplified Oncol 2016;34:3740-8. in combination with ipilimumab in small-
gene in small-cell lung cancer. Nat Genet 14. Herbst RS, Soria JC, Kowanetz M, et al. cell lung cancer. Cancer Cell 2018;33(5):
2012;44:1111-6. Predictive correlates of response to the 853-861.e4.
6. Peifer M, Fernández-Cuesta L, Sos ML, anti-PD-L1 antibody MPDL3280A in cancer 25. Hellmann MD, Nathanson T, Rizvi H,
et al. Integrative genome analyses identify patients. Nature 2014;515:563-7. et al. Genomic features of response to
key somatic driver mutations of small-cell 15. Tecentriq (atezolizumab):summary of combination immunotherapy in patients
lung cancer. Nat Genet 2012;44:1104-10. product characteristics. Basel, Switzerland: with advanced non-small-cell lung cancer.
7. Rizvi H, Sanchez-Vega F, La K, et al. Roche Registration GmbH (http://www.ema Cancer Cell 2018;33(5):843-852.e4.
Molecular determinants of response to .europa.eu/docs/en_GB/document_library/ 26. Rittmeyer A, Barlesi F, Waterkamp D,
anti-programmed cell death (PD)-1 and EPAR_-_ Product_Information/human/ et al. Atezolizumab versus docetaxel in
anti-programmed death-ligand (PD-L)- 004143/WC500235778.pdf). patients with previously treated non-small-
ligand 1 blockade in patients with non- 16. Micke P, Faldum A, Metz T, et al. cell lung cancer (OAK): a phase 3, open-
small-cell lung cancer profiled with tar- Staging small cell lung cancer: Veterans label, multicentre randomised controlled
geted next-generation sequencing. J Clin Administration Lung Study Group versus trial. Lancet 2017;389:255-65.
Oncol 2018;36:633-41. International Association for the Study of 27. Cortinovis D, von Pawel J, Syrigos K,
8. Antonia SJ, López-Martin JA, Bendell J, Lung Cancer — what limits limited dis- et al. Immune-related adverse events
et al. Nivolumab alone and nivolumab plus ease? Lung Cancer 2002;37:271-6. (irAEs) in advanced NSCLC patients treat-
ipilimumab in recurrent small-cell lung 17. Ishii H, Azuma K, Kawahara A, et al. ed with atezolizumab: safety population
cancer (CheckMate 032): a multicentre, Significance of programmed cell death- analyses from the Ph III study OAK. Ann
open-label, phase 1/2 trial. Lancet Oncol ligand 1 expression and its association Oncol 2017;28:Suppl 5:1313P. abstract.
2016;17:883-95. with survival in patients with small cell 28. Fehrenbacher L, Spira A, Ballinger M,
9. Ott PA, Elez E, Hiret S, et al. Pembro- lung cancer. J Thorac Oncol 2015;10:426-30. et al. Atezolizumab versus docetaxel for
lizumab in patients with extensive-stage 18. Schultheis AM, Scheel AH, Ozretić L, patients with previously treated non-
small-cell lung cancer: results from the et al. PD-L1 expression in small cell neuro- small-cell lung cancer (POPLAR): a multi-
Phase Ib KEYNOTE-028 study. J Clin On- endocrine carcinomas. Eur J Cancer 2015; centre, open-label, phase 2 randomised
col 2017;35:3823-9. 51:421-6. controlled trial. Lancet 2016;387:1837-46.
10. Sequist LV, Chiang A, Gilbert J, et al. 19. Gandara DR, Paul SM, Kowanetz M, Copyright © 2018 Massachusetts Medical Society.